MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks
Home » How the Belmont Report clarified informed consent

How the Belmont Report clarified informed consent

February 8, 2019 By Danielle Kirsh Leave a Comment

Share

imarcSandra Maddock, President & CEO, IMARC Research

Imagine being enrolled in a clinical trial without fully understanding the scope or the risks.

The Belmont Report marks an important milestone in the history of clinical research. It established guidelines for basic ethical principles, as well as informed consent, the assessment of risks and benefits and subject selection.

In this post, we’ll discuss the key principles of the report, and in particular, how it clarified our understanding of informed consent.

What is the Belmont Report?

The Belmont Report was written in response to the infamous Tuskegee Syphilis Study, in which African Americans with syphilis were lied to and denied treatment for more than 40 years. Many people died as a result, infected others with the disease, and passed congenital syphilis onto their children.

Following the Tuskegee study, Congress passed the National Research Act, creating the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. This commission met regularly for nearly four years, culminating in a four-day discussion at the Smithsonian Institution’s Belmont Conference Center in February 1976.

The resulting Belmont Report summarized the three ethical principles the commission concluded should guide human research:

  • Respect for persons: All individuals should be treated as autonomous agents, and persons with diminished autonomy are entitled to protection
  • Beneficence: Researchers should maximize possible benefits and minimize possible harm
  • Justice – All persons should be treated equally, and the selection of research subjects should be scrutinized so that no one is systematically selected on the basis of race, ethnicity, class or other factors

The Belmont Report remains a primary ethical framework for researchers today.

How the Belmont Report defines informed consent

The Belmont Report addresses informed consent as a necessary part of showing respect for all persons. It states that all subjects, to the degree that they are capable, should be given the opportunity to choose what shall or shall not happen to them.

According to the report, informed consent requires three elements: information, comprehension and voluntariness.

Information

Research subjects “must be given sufficient information about the research procedure, their purposes, risks and anticipated benefits and alternative procedures (where therapy is involved).” They should be given the opportunity to ask questions and have the right to withdraw from the research at any time.

In cases where informing subjects about some pertinent aspect of the research is likely to impair the validity of the research, the Belmont Report states withholding information is justified only if the following three criteria apply:

  1. Incomplete disclosure is truly necessary to accomplish the goals of the research
  2. There are no undisclosed risks to subjects that are more than minimal
  3. There is an adequate plan for debriefing subjects, when appropriate, and for disseminating research results to them

Researchers should never withhold information about risks for the purpose of getting a subject to cooperate.

Comprehension

The Belmont Report states that “the manner and context in which information is conveyed is as important as the information itself.” For instance, allowing too little time for the subject to consider the information could affect their ability to make an informed choice.

That means researchers need to consider a subject’s maturity, capacity for understanding, language and literacy when presenting information to obtain informed consent. In some cases, the report states, it may be appropriate to give oral or written tests of comprehension.

 

Related: What Does “Understandable Language” Mean In Informed Consent?

When a subject’s comprehension is severely limited due to age, disability or other factors, researchers need to seek the permission of other parties to protect them from harm.

Voluntariness

Informed consent means there is no coercion or undue influence. In other words, researchers cannot threaten harm or offer an “excessive, unwarranted, inappropriate or improper reward” to obtain compliance.

That means researchers need to take special care when conducting clinical trials involving vulnerable people who are under the authority of someone else, such as inmates or people who are ill.

Other considerations involving informed consent

On the surface, informed consent seems like a straightforward concept. However, the evolution of clinical research and the introduction of new technologies continue to raise new questions about its application.

For instance:

  • What additional considerations apply when informed consent is obtained electronically?
  • How can researchers avoid overstating the potential benefits of a medical device?
  • How can researchers avoid undue influence when enrolling employees in a clinical trial?

The FDA released its latest guidance on informed consent in 1998 and has drafted an update to that document that has yet to be finalized. While it’s not likely we’ll ever see the “last word” on informed consent, the Belmont Report serves as an important and timeless reminder of the fundamentals of informed consent.

Curious to learn more about the origins of informed consent, Good Clinical Practice and other research guidelines? Explore the history of clinical research in this interactive timeline.

The opinions expressed in this blog post are the author’s only and do not necessarily reflect those of MassDevice.com or its employees.

Filed Under: Blog Tagged With: IMARC

In case you missed it

  • Here’s how a new Abbott device is making a difference among neonatal infants
  • Conformis: Yale study shows customized knee implants save money
  • Intuitive Surgical wins FDA clearance for robotic-assisted lung biopsy system
  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
  • Phillips-Medisize is expanding in Wisconsin
  • NuVasive wins FDA, CE Mark for Precice internal bone transport system
  • Cash-strapped Aradigm declares bankruptcy
  • ReWalk Robotics files for exoskeleton suit clearance
  • Hancock Jaffe launches first-in-human VenoValve study
  • Medtronic shares rise on FY2019 Q3 earnings beat
  • Medtronic: Patient deaths left out of paclitaxel-coated balloon analysis
  • Teva aims for 25% of U.S. EpiPen market by 2020
  • Medtronic wins FDA’s breakthrough status for closed-loop insulin system
  • India CDSCO adds new medical devices to regulated list
  • Judge sends ‘brain fingerprinting company’ and would-be distributor to arbitration
  • FDA gives massive Medtronic recall Class I designation
  • Affluent Medical touts results of endovascular aneurysm repair study

RSS From Medical Design & Outsourcing

  • Medtronic risk prediction tool could help prevent opioid deaths: Here’s how
    Medtronic officials continue to hone their arguments for how the company’s capnography and oximetry systems could reduce potentially deadly opioid-induced respiratory compromise. The medical device giant on Feb. 17 announced preliminary results of its Prodigy study, in which the company’s Microstream and Nellcor monitoring technology provided continuous capnography and oximetry for 1,496 patients across 16 sites in the U.S.,… […]
  • Phillips-Medisize is expanding in Wisconsin
    Phillips-Medisize, a Molex company, has broken ground on a new manufacturing facility in Hudson, Wis., on the eastern end of the Minneapolis-St. Paul metro area. The 34-acre location at the St. Croix Meadows development will support at least 230,000 square feet of manufacturing space for FDA-regulated medical device products, Phillips-Medisize announced yesterday. After construction is complete… […]
  • ReWalk Robotics files for exoskeleton suit clearance
      ReWalk Robotics (NSDQ:RWLK) said it has applied to FDA for 510(k) clearance of its ReStore exoskeleton suit for gait training during stroke rehabilitation. The Yokneam, Israel-based company designed its exo-suit to provide coordinated plantarflexion and dorsiflexion assistance to a patient’s foot and ankle. It recently won insurer reimbursement from Cigna and completed a clinical… […]
  • FDA proposes faster post-inspection feedback
    FDA has issued draft guidance providing for more timely nonbinding feedback following medtech facility inspections to advise whether the companies’ proposed corrective actions appear adequate to the agency. The draft guidance proposes a process by which companies can request nonbinding feedback on certain kinds of observations issued on a Form 483. It outlines a standardized method… […]
  • India CDSCO adds new medical devices to regulated list
    By Stewart Eisenhart, Emergo Group India’s Central Drugs Standard Control Organization (CDSCO) continues expanding oversight to more types of medical devices, now planning to require registration for eight additional device types starting April 1, 2020. Get the full story here at the Emergo Group’s blog. The opinions expressed in this blog post are the author’s… […]
  • Empowering Medical Innovation
    From faster medical device development to life-saving surgical planning models, see how full-color, multi-material 3D printing opens up broad possibilities for medical innovation. In this new E-book you’ll learn how the Stratasys J750 can: Produce superior medical models for surgical planning and training Foster better medical devices through faster ideation and prototyping Enable advanced training… […]
  • Affluent Medical touts results of endovascular aneurysm repair study
    Medtech startup Affluent Medical(Paris, France) said a study of its endovascular aneurysm repair (EVAR) system device showed patients had fewer endoleaks and needed fewer secondary interventions, and that their aneurysms shrank in volume and diameter. The company’s Kardiozis endovascular prosthesis uses thrombogenic fibers to embolize an abdominal aortic aneurism sac during a conventional EVAR procedure to prevent… […]
  • This cotton-based biofuel cell could power implanted medical devices
    Researchers at the Georgia Institute of Technology and Korea University have developed a glucose-powered biofuel cell that uses electrodes from cotton that could potentially power implantable medical devices. The fuel cell has twice as much power as traditional biofuel cells and could also be paired with batteries or super capacitors to create a hybrid power… […]
  • IEEE publishes safety standards draft for medtech interoperability
    The Institute of Electrical and Electronics Engineers (IEEE) Standards Association said it has published a draft set of standards intended to provide safe and secure medical device interoperability. IEEE 11073-20701-2018, also known as IEEE Approved Draft Standard for Service-Oriented Medical Device Exchange Architecture & Protocol Binding, completes the International Organization for Standardization (ISO)/IEEE 11073 family of standards… […]
  • FDA clears Safe Medical Design’s urethral catheter
    Safe Medical Design (San Francisco) said that FDA has cleared its Signal Catheter for commercialization in the United States. The 100% silicone foley catheter features a novel hub design allowing the catheter to reduce excessive balloon pressure in the event the catheter is improperly placed. Each year in the United States there are as many as 500,000… […]
  • These medtech companies raised the most VC in 2018
    Venture capital firms invested more than $2.9 billion in medical device companies in 2018 — a slight increase from the $2.8 billion raised in 2017, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Both the first and second quarters of 2018 saw an increase in investments, totaling nearly $778 million and $786 million respectively.… […]

Leave a Reply Cancel reply

You must be logged in to post a comment.

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS